DataCiterelevance policy v2
Eficácia e segurança do uso da Cannabis sativa no tratamento dos sintomas não-motores na Doença de Parkinson: uma revisão de escopo
DataCiterelevance policy v2
Parkinson-CBD
DataCiterelevance policy v2
Research Appendix to "Chronic Endocannabinoid Deficiency as the Root Cause of Aging and Death by Natural Causes": 360 Cannabis-Related Studies Supporting the ECS Model
DataCiterelevance policy v2
Treatment of non-motor symptoms of Parkinson's disease with Cannabidiol - RBR-3tvjjkx - Statistical Analysis Plan
DataCiterelevance policy v2
Parkinson's Disease as a Potential Stuck Program Mode of the Candida albicans Biochemical Computer
DataCiterelevance policy v2
Investigating the potential of targeting the CB2 receptor for anti-inflammatory disease modification in Parkinson’s disease
DataCiterelevance policy v2
A Novel Microglial Cannabinoid Receptor 2 Knockout Mouse Line: Relevance For Parkinson's Disease & L-DOPA Induced Dyskinesia
DataCiterelevance policy v2
Chronic Endocannabinoid Deficiency as the Root Cause of Aging and Death by Natural Causes — A Systems Model Approach as a Means to Reach Longevity Escape Velocity
DataCiterelevance policy v2
Chronic Endocannabinoid Deficiency as the Root Cause of Aging and Death by Natural Causes — A Systems Model Approach as a Means to Reach Longevity Escape Velocity
DataCiterelevance policy v2
Beta-caryophyllene inhibits the permeability of the blood–brain barrier in MPTP-induced parkinsonism
DataCiterelevance policy v2
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications
DataCiterelevance policy v2
Loss of cannabinoid cb1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of parkinson's disease in the rat
DataCiterelevance policy v2
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
DataCiterelevance policy v2
Cannabidiol and Parkinson's disease: Investigating receptor interactions and their therapeutic implications
DataCiterelevance policy v2
Beta-caryophyllene inhibits the permeability of the blood–brain barrier in MPTP-induced parkinsonism
DataCiterelevance policy v2
Definitive Cure for Parkinson's Disease — Regeneration or Protection of Dopaminergic Cells via the Hamzah Model.
DataCiterelevance policy v2
Parkinson-CBD
DataCiterelevance policy v2
Investigating the role of neuroinflammation in a mouse model of L-Dopa induced dyskinesia and exploring the anti-dyskinetic potential of a cannabinoid receptor agonist
DataCiterelevance policy v2
Definitive Cure for Parkinson's Disease — Regeneration or Protection of Dopaminergic Cells via the Hamzah Model.
DataCiterelevance policy v2
Investigation of monoacyglycerol lipase inhibition for disease modification in animal models of Parkinson’s disease: behavioural, neurochemical and histological investigations as well as biomarker evaluation